Abstract
Background and objective
Nontuberculous mycobacterial pulmonary disease (NTM-PD) prevalence in Japan is among the highest worldwide. COPD and bronchiectasis are common comorbidities among patients with NTM-PD, and it is challenging to treat NTM-PD in patients with these conditions. There are limited data on the incremental burden that NTM-PD adds to underlying COPD or bronchiectasis in Japan. Therefore, the objective of this study was to assess the incremental burden associated with NTM-PD in patients with pre-existing COPD and/or bronchiectasis.
Methods
This nested case–control study was based on JMDC, Inc. claims data (2015–2020). Patients with COPD and/or bronchiectasis with NTM-PD (cases) were age and sex matched 1:3 to patients with COPD and/or bronchiectasis without NTM-PD (controls), resulting in three mutually exclusive patient groups (COPD, bronchiectasis or both; with or without NTM-PD). Incremental burden of NTM-PD was assessed within each group by comparing hospitalisations during the 1-year period after NTM-PD diagnosis (index) between cases and controls with both univariate analysis and multivariate analysis adjusting for pre-index comorbidities.
Results
Univariate analyses in the three patient groups consistently demonstrated incremental hospitalisation burden in cases versus controls (e.g. COPD group: 20% of 492 cases versus 13% of 1476 controls had all-cause hospitalisations; 11% versus 5% had respiratory-related hospitalisations; and 6% versus 2% had COPD-related hospitalisations). Subsequent multivariate analysis further confirmed the findings.
Conclusions
The substantial incremental burden of hospitalisation associated with NTM-PD in patients with COPD and/or bronchiectasis highlights the urgent need for appropriate management of NTM-PD in Japan.
Shareable abstract
NTM-PD is a progressive, debilitating lung infection. This nested case–control study found NTM-PD added substantial hospitalisation burden to pre-existing COPD and/or bronchiectasis in Japan, highlighting the urgent need for appropriate NTM-PD management. https://bit.ly/49Gr7YH
Introduction
Nontuberculous mycobacterial pulmonary disease (NTM-PD) is a progressive and debilitating pulmonary infection associated with increased healthcare utilisation [1–3]. Prevalence of NTM-PD varies globally [4] with reported increases in the USA, Germany and Korea [5–7]. The estimated prevalence rate of NTM-PD in Japan is among the highest reported: 29 per 100 000 persons (2011) [8]. The estimated incidence of NTM-PD in Japan has increased from ∼5.7 per 100 000 person-years in 2007 to 14.7 per 100 000 person-years in 2014) [9]. The markedly higher prevalence relative to incidence estimates may be due to NTM-PD being chronic and difficult to treat [2, 8].
Patients with NTM-PD often have comorbid respiratory conditions such as COPD and bronchiectasis [1, 10–12]. In an administrative claims-based analysis, patients with NTM-PD were six times more likely to have comorbid COPD than those without [13]. Prevalence of bronchiectasis in Japan is unclear [14]; however, the frequency of comorbid bronchiectasis among patients with NTM-PD ranges from <5% to >80% [2, 8, 10, 15]. Such large variations may be attributable to low reports of bronchiectasis by physicians in insurance claims but much higher rates of bronchiectasis confirmed by chest images available in hospital records [2, 8, 10, 15].
Diagnosis of NTM-PD may be delayed [16–18], particularly in patients with pre-existing lung diseases, such as COPD or bronchiectasis, due to nonspecific, overlapping symptoms (e.g. cough or shortness of breath) [1, 16–20]. Delays in diagnosis and treatment of NTM-PD in patients with coexisting lung diseases can contribute to disease progression and poor clinical outcomes [21, 22]. Notably, current international clinical practice guidelines for NTM-PD recommend timely treatment initiation rather than “watchful waiting”, especially for patients with positive acid-fast bacilli sputum smears and/or cavitary lung disease [23].
US-based investigations have reported that NTM-PD has been associated with significantly higher hospitalisation burden among patients with underlying COPD or bronchiectasis [3, 24]; however, the incremental burden that NTM-PD may add to pre-existing COPD and/or bronchiectasis in Japan is under-researched. The objective of this study was to assess the incremental burden that NTM-PD adds to patients with pre-existing COPD, bronchiectasis, or concomitant bronchiectasis and COPD in Japan by comparing hospitalisations between patients with NTM-PD versus those without NTM-PD. Such fine segmentation of the patient population may allow more precise characterisation of the burden of NTM-PD in these high-risk patients and enable appropriate healthcare resource allocation and timely management of NTM-PD.
Methods
Data source
This nested case–control study was conducted using claims data provided by the JMDC, Inc. (formerly Japan Medical Data Centre) from 1 February 2015 to 29 February 2020 (representing 6 504 929 lives in total). The JMDC contracts with multiple Japanese health insurance societies and has accumulated reimbursement data, consisting of receipts (inpatient, outpatient and dispensing) and medical examination data, from enrolled employees and their dependents (age range, from birth to 74 years) [25]. Ethics approval was not required based on the Ethical Guidelines for Medical and Biological Research Involving Human Subjects [26] since only publicly available de-identified and encrypted data were used [25].
Study population
JMDC database members with NTM-PD and pre-existing comorbid COPD and/or bronchiectasis were identified as meeting the following requirements: 1) a diagnosis of NTM-PD; and 2) a diagnosis of either COPD, both COPD and bronchiectasis, or bronchiectasis alone, before the first diagnosis of NTM-PD. All eligible patients with COPD and/or bronchiectasis and NTM-PD (cases) were matched 1:3 to patients with COPD and/or bronchiectasis without NTM-PD (controls) by age on index date and sex, forming three mutually exclusive case–control patient groups (table 1).
TABLE 1.
Definitions of case patients and control patients in the three mutually exclusive case–control patient groups for assessing incremental burden of nontuberculous mycobacterial pulmonary disease (NTM-PD)
| Patient groups | |||
|---|---|---|---|
| COPD | Bronchiectasis and COPD | Bronchiectasis | |
| Cases#: NTM-PD | Pre-existing COPD¶ No bronchiectasis |
Pre-existing bronchiectasis¶ Pre-existing COPD¶ |
Pre-existing bronchiectasis¶ No COPD |
| Controls#: no NTM-PD | COPD No bronchiectasis |
Bronchiectasis and COPD | Bronchiectasis No COPD |
#: within each mutually exclusive case–control patient group, cases were matched 1:3 to age- and sex-matched controls; ¶: COPD and/or bronchiectasis preceded index date (i.e. date that the first claim with NTM-PD diagnosis (International Classification of Diseases, 10th revision, A31.0 and A31.9) was received).
The index date for cases was defined as date of first medical claim with a diagnosis of NTM-PD. The index date for controls was a uniformly distributed random date after diagnosis of COPD and/or bronchiectasis. All cases and matched controls had continuous health insurance coverage from 1 year pre-index to 1 year post-index.
Definitions of patients with NTM-PD, COPD and bronchiectasis
A patient with NTM-PD was defined as an individual with two or more claims with a diagnostic code for NTM-PD (International Classification of Diseases, 10th Revision, Clinical Modification (ICD-10-CM) A31.0 and A31.9) in two different months but within 12 months, from ambulatory or inpatient encounters [5, 27]. A patient with COPD was defined as an individual who had either two or more ambulatory encounters with a diagnostic code for COPD (ICD-10-CM J41–J44) in two different months, or one or more hospitalisations with a diagnostic code for COPD [28]. A patient with bronchiectasis was defined as an individual with either two or more ambulatory encounters with a diagnostic code for bronchiectasis (ICD-10-CM J47) in two different months, or one or more ambulatory encounter with a bronchiectasis diagnosis and a computed tomography scan of the thorax (Current Procedural Terminology 4 codes 71250, 71260 and 71270) within 2 months before the encounter, or one or more inpatient claims with a diagnostic code for bronchiectasis [28]. The identification of patients with NTM-PD, COPD and bronchiectasis was similar to validated approaches based on ICD-10-CM or ICD-9-CM codes [5, 27, 28].
Study outcomes
Over the 1-year post-index follow-up period, all-cause, respiratory-related, COPD-related and bronchiectasis-related hospitalisations were compared between cases and controls by: 1) proportions of patients who were hospitalised; and 2) annual hospitalisation rate (number of hospitalisations per patient per year (PPPY)). Respiratory-related hospitalisations were defined as hospitalisations with a diagnosis for respiratory conditions (ICD-10-CM J00–J99). Likewise, COPD- and bronchiectasis-related hospitalisations were defined as those with diagnosis for COPD and bronchiectasis, respectively.
Statistical analysis
Descriptive analyses of demographics including age at index date, sex and insured status as well as clinical characteristics during the 1-year pre-index period were conducted for patients with both COPD and/or bronchiectasis and NTM-PD (cases) and matched patients with COPD and/or bronchiectasis without NTM-PD (controls).
The incremental burden of hospitalisation associated with NTM-PD in patients with pre-existing COPD and/or bronchiectasis was analysed with univariate analysis of hospitalisations accrued over the 1-year post-index follow-up period, including 1) proportion of patients hospitalised and 2) number of hospitalisations PPPY, followed with multivariate analyses controlling for confounding comorbidities during the 1-year pre-index period, including logistic regression for estimating the adjusted odds ratio of hospitalisation and Poisson regression for estimating the adjusted hospitalisation incidence rate ratio (IRR). Comorbidities were identified based on a single occurrence of corresponding diagnostic ICD-10-CM codes in any medical claim (table S1).
Categorical variables are presented as the number and proportion of patients; continuous variables are summarised by mean and standard deviation, median, and quartiles. Statistical tests comparing the case versus control groups included McNemar's test for categorical variables and the Wilcoxon signed-rank test for continuous variables. An α=0.05 was considered statistically significant.
Results
Study population
We identified 492 case patients with COPD with NTM-PD, 37 with bronchiectasis and COPD with NTM-PD, and 53 with bronchiectasis with NTM-PD. Each of these case patients was matched by age and sex to 1476 control patients with COPD without NTM-PD, 111 with bronchiectasis and COPD without NTM-PD, and 159 with bronchiectasis without NTM-PD (figure S1).
Demographics and pre-index clinical characteristics
Age at index date (mean±sd 56.6±10.3, 58.1±9.5 and 58.5±9.4 years in the COPD, bronchiectasis and COPD, and bronchiectasis groups, respectively) (table 2) and time between diagnosis of COPD/bronchiectasis and subsequent diagnosis of NTM-PD (approximately 1 year) were similar in all groups.
TABLE 2.
Patient demographics and clinical characteristics during the 1-year pre-index period
| COPD group | Bronchiectasis and COPD group | Bronchiectasis group | ||||
|---|---|---|---|---|---|---|
| Case: with NTM-PD | Control: without NTM-PD | Case: with NTM-PD | Control: without NTM-PD | Case: with NTM-PD | Control: without NTM-PD | |
| Subjects | 492 | 1476 | 37 | 111 | 53 | 159 |
| Age at index date, years, mean±sd | 56.6±10.3 | 56.6±10.3 | 58.1±9.5 | 58.1±9.4 | 58.5±9.4 | 58.5±9.4 |
| Female | 302 (61.4) | 906 (61.4) | 28 (75.7) | 84 (75.7) | 42 (79.2) | 126 (79.2) |
| Insured status | ||||||
| Insured employee | 265 (53.9) | 837 (56.7) | 14 (37.8) | 48 (43.2) | 22 (41.5) | 70 (44.0) |
| Employee dependent | 227 (46.1) | 639 (43.3) | 23 (62.2) | 63 (56.8) | 31 (58.5) | 89 (56.0) |
| Selected nonpulmonary comorbidities | ||||||
| All cardiovascular diseases# | 210 (42.7) | 834 (56.5) | 11 (29.7) | 51 (46.0) | 20 (37.7) | 67 (42.1) |
| GORD# | 173 (35.2) | 541 (36.7) | 10 (27.0) | 35 (31.5) | 15 (28.3) | 38 (23.9) |
| Hypertension# | 120 (24.4) | 649 (44.0) | 6 (16.2) | 39 (35.1) | 13 (24.5) | 46 (28.9) |
| All cancers, excluding lung cancer# | 87 (17.7) | 193 (13.1) | 2 (5.4) | 12 (10.8) | 7 (13.2) | 15 (9.4) |
| Diabetes mellitus# | 40 (8.1) | 146 (9.9) | 2 (5.4) | 7 (6.3) | 5 (9.4) | 15 (9.4) |
| Chronic kidney disease# | 5 (1.0) | 42 (2.8) | 0 (0.0) | 3 (2.7) | 0 (0) | 3 (1.9) |
| Dementia# | 4 (0.8) | 22 (1.5) | 0 (0.0) | 2 (1.8) | 0 (0.0) | 0 (0.0) |
| Overweight and obesity# | 2 (0.4) | 31 (2.1) | 0 (0.0) | 1 (0.9) | 1 (1.9) | 0 (0) |
| Selected pulmonary symptoms | ||||||
| Haemoptysis | 54 (11.0) | 25 (1.7) | 7 (18.9) | 10 (9.0) | 10 (18.9) | 13 (8.2) |
| Cough | 27 (5.5) | 57 (3.9) | 5 (13.5) | 6 (5.4) | 1 (1.9) | 6 (3.8) |
| Dyspnoea | 8 (1.6) | 9 (0.6) | 2 (5.4) | 1 (0.9) | 0 (0) | 1 (0.63) |
| Selected pulmonary comorbidities | ||||||
| Asthma# | 182 (37.0) | 652 (44.2) | 10 (27.0) | 48 (43.2) | 17 (32.1) | 55 (34.6) |
| Pneumonia | 154 (31.3) | 245 (16.6) | 14 (37.8) | 28 (25.2) | 20 (37.7) | 67 (24.5) |
| Emphysema | 64 (13.0) | 187 (12.7) | 3 (8.1) | 6 (5.4) | 0 (0.0) | 0 (0.0) |
| Malignant neoplasm of bronchus and lung | 34 (6.9) | 55 (3.7) | 0 (0.0) | 3 (2.7) | 1 (1.9) | 1 (0.6) |
| Idiopathic interstitial lung disease# | 26 (5.3) | 54 (3.7) | 4 (10.8) | 9 (8.1) | 0 (0) | 4 (2.5) |
| Patients with annual health check-up record | 311 | 927 | 24 | 62 | 30 | 105 |
| Habitual smoker based on annual health check-up¶ | 41 (13.2) | 207 (22.3) | 0 (0.0) | 11 (18.0) | 1 (3.3) | 7 (6.7) |
Data are presented as n or n (%), unless otherwise stated. Comorbidities that were not significantly different between cases and controls (p≥0.05): pneumonia, gastro-oesophageal reflux disease (GORD), and hypertension in the bronchiectasis and COPD group and the bronchiectasis group, and asthma in the bronchiectasis group; all other comorbidities with non-zero patient counts were significantly different between cases and controls in each group; p-values met the statistical significance level (α=0.05) based on McNemar's test. NTM-PD: nontuberculous mycobacterial pulmonary disease. #: comorbidities included in the multivariate analyses. ¶: habitual smokers were identified using annual health check-up records during the 1-year pre-index period. Not all patients had annual check-up records. The percentages for habitual smokers were calculated based on the number of patients with annual check-up records. Statistical difference was tested with the Chi-squared test to accommodate the fact that only a subset of the matched patients had annual check-up data and a statistically significant difference was observed between cases and controls in the COPD group (p<0.05).
Clinical characteristics were evaluated during the 1-year pre-index period (table 2). Comorbidities that were consistently less common in cases with NTM-PD versus controls without NTM-PD included all cardiovascular diseases (42.7% versus 56.5% in the COPD group; 29.7% versus 46.0% in the bronchiectasis and COPD group; 37.7% versus 42.1% in the bronchiectasis group; all p<0.05), hypertension (24.4% versus 44.0% in the COPD group, p<0.05; 16.2% versus 35.1% in the bronchiectasis and COPD group, p>0.05; 24.5% versus 28.9% in the bronchiectasis group, p>0.05) and diabetes (8.1% versus 9.9% in the COPD group, 5.4% versus 6.3% in the bronchiectasis and COPD group, 9.4% versus 9.4% in the bronchiectasis group; all p<0.05). Gastro-oesophageal reflux disease (GORD) had no statistically significant difference between cases and controls in the bronchiectasis and COPD (27.0% versus 31.5%) and bronchiectasis (28.3% versus 23.9%) groups. GORD was more common among patients with COPD (cases 35.2% versus controls 36.7%; p<0.05) versus those with bronchiectasis, regardless of the presence of NTM-PD.
Pulmonary symptoms and comorbidities generally occurred in a higher proportion of cases compared with controls in each patient group except asthma (table 2). Asthma was the most common pulmonary comorbidity overall and was consistently lower among cases than controls in all patient groups (37.0% versus 44.2% in the COPD group, p<0.05; 27.0% versus 43.2% in the bronchiectasis and COPD group, p<0.05; 32.1% versus 34.6% in the bronchiectasis group, p>0.05). Haemoptysis was more common in cases than controls across all groups and was more prevalent among patients with comorbid bronchiectasis (11.0% versus 1.7% in the COPD group, p<0.05; 18.9% versus 9.0% in the bronchiectasis and COPD group, p<0.05; 18.9% versus 8.2% in the bronchiectasis group, p<0.05). Pneumonia was more common in cases than in controls across groups and more prevalent among patients with comorbid bronchiectasis (31.3% versus 16.6% in the COPD group, p<0.05; 37.8% versus 25.2% in the bronchiectasis and COPD group, p>0.05; 37.7% versus 24.5% in the bronchiectasis group, p>0.05).
Incremental hospitalisation burden associated with NTM-PD in patients with COPD
Proportion of patients with hospitalisations
Univariate analysis found that a significantly higher proportion of patients with COPD with NTM-PD had hospitalisations than matched controls with COPD without NTM-PD: 20% of cases versus 13% of controls experienced an all-cause hospitalisation, 11% versus 5% a respiratory-related hospitalisation, and 6% versus 2% a COPD-related hospitalisation (all p<0.001) (figure 1a).
FIGURE 1.
a) Proportion of patients with hospitalisations over a 1-year follow-up period in patients with COPD and NTM-PD versus matched patients with COPD without NTM-PD and b) odds ratios associated with nontuberculous mycobacterial pulmonary disease (NTM-PD) after multivariate analysis adjustment (ORs derived from logistic regression analysis controlling for comorbidities during the 1-year pre-index period: diabetes mellitus; hypertension; overweight and obesity; chronic kidney disease; total cardiovascular diseases; cancer, excluding lung; dementia; gastro-oesophageal reflux disease; asthma; idiopathic pulmonary fibrosis; and idiopathic interstitial lung disease). Data are presented as a) n (%) and b) OR (95% CI). ***: p<0.001 based on McNemar's test for differences between cases and controls.
After multivariate logistic regression analysis controlling for pre-index confounding comorbidities, patients with COPD with NTM-PD were OR 1.9 (95% CI 1.4–2.5), 2.8 (95% CI 1.9–4.1) and 3.0 (95% CI 1.8–5.2) times more likely to experience an all-cause, respiratory-related, and COPD-related hospitalisation, respectively (figure 1b).
Annualised hospitalisation rates
Univariate analysis found a significantly higher hospitalisation rate among patients with COPD with NTM-PD than among controls with COPD without NTM-PD (figure 2a). Mean±sd hospitalisations per patient over the 1-year post-index period in cases versus controls was 0.19±0.67 versus 0.08±0.44 (p<0.001) for respiratory-related hospitalisations. Similar statistically significant differences were observed for all-cause and COPD-related hospitalisations (p<0.001) (figure 2a).
FIGURE 2.
a) Per-patient rates of hospitalisation over a 1-year follow-up period in patients with COPD and NTM-PD versus matched patients with COPD without NTM-PD and b) incidence rate ratios (IRRs) associated with nontuberculous mycobacterial pulmonary disease (NTM-PD) after multivariate analysis adjustment (IRR is a ratio of incidence rate between the two groups being compared; IRR values derived from Poisson regression analysis controlling for comorbidities during the 1-year pre-index period: diabetes mellitus; hypertension; overweight and obesity; chronic kidney disease; total cardiovascular diseases; cancer, excluding lung; dementia; gastro-oesophageal reflux disease; asthma; idiopathic pulmonary fibrosis; and idiopathic interstitial lung disease). Data are presented as a) mean±sd and b) IRR (95% CI). ***: p<0.001 based on Wilcoxon signed-rank test for differences between cases and controls.
After multivariate Poisson regression analysis controlling for confounding pre-index comorbidities, patients with COPD and NTM-PD had IRR 1.7 (95% CI 1.4–2.0), 2.5 (95% CI 1.9–3.3) and 2.5 (95% CI 1.7–3.7) times the rate of all-cause, respiratory-related and COPD-related hospitalisations (figure 2b).
A subgroup analysis among hospitalised patients in the COPD group during the 1-year post-index follow-up further examined the impact of NTM-PD in hospitalised patients with COPD. There were no significant differences between cases and controls in either number of admissions per patient (mean 1.6, p=0.6) or length of stay per patient (mean 12–13 days, p=0.4) (table S2).
Incremental hospitalisation burden associated with NTM-PD in patients with bronchiectasis
Proportion of patients with hospitalisations
Univariate analysis found that a significantly higher proportion of patients with bronchiectasis and COPD with NTM-PD experienced hospitalisations than matched controls with bronchiectasis and COPD without NTM-PD: 24.3% versus 9.9% for all-cause, 16.2% versus 3.6% for respiratory-related, 5.4% versus 0.9% for bronchiectasis-related, and 8.1% versus 1.8% for COPD-related hospitalisations (all p<0.05) (figure 3a). Similarly, among patients with bronchiectasis with NTM-PD, the proportion with hospitalisations was significantly greater than that of matched controls with bronchiectasis without NTM-PD for all hospitalisation categories evaluated (all p<0.001) (figure 3c).
FIGURE 3.
a) Proportion of patients with hospitalisations* and b) per-patient rates of hospitalisation‡ in patients with bronchiectasis and COPD with nontuberculous mycobacteriual pulmonary disease (NTM-PD) versus matched patients with bronchiectasis and COPD without NTM-PD; and c) proportion of patients with hospitalisations* and d) per-patient rates of hospitalisation‡ in patients with bronchiectasis with NTM-PD versus matched patients with bronchiectasis without NTM-PD in Japan over a 1-year follow-up period. Data are presented as a and c) percentages or b and d) mean±sd. p-values represent between-group comparisons based on a and c) McNemar's test and b and d) Wilcoxon signed-rank test. ***: p<0.001; #: p<0.02; ¶: p<0.03; +: p<0.009; §: p=0.095; ƒ: p=0.071; ##: p<0.006; ¶¶: p<0.005.
Annualised hospitalisation rates
Univariate analysis found that all-cause and respiratory-related hospitalisation rates were significantly higher in patients with bronchiectasis and COPD with NTM-PD than in those with bronchiectasis and COPD without NTM-PD (both p<0.05) (figure 3b).
Among patients with bronchiectasis with NTM-PD, the hospitalisation rates were significantly higher for all-cause, respiratory-related, and bronchiectasis-related hospitalisations compared with matched controls with bronchiectasis without NTM-PD (all p<0.05) (figure 3d).
Discussion
This study shows that patients in Japan with NTM-PD and pre-existing COPD and/or bronchiectasis were significantly more likely to experience hospitalisation and had higher rates of hospitalisation than patients with COPD and/or bronchiectasis without NTM-PD.
Our findings are comparable with a retrospective US Medicare claims database study (2010–2017) that evaluated incremental healthcare resource utilisation in 4010 patients with COPD with NTM-PD and 12 030 age/sex-matched controls with COPD without NTM-PD [3]. That study found patients with COPD and NTM-PD were approximately two times more likely to experience an all-cause, respiratory-related and COPD-related hospitalisation than those with COPD without NTM-PD [3].
A German population-based cohort study found hospitalisation burden among patients with NTM-PD was three times higher than in age/sex/Charlson Comorbidity Index-matched controls without NTM-PD; mortality risk was four-fold higher over the 39-month follow-up period [29]. The mortality rate in patients with COPD with NTM-PD (41.5%; 27/65) was >2 times higher than in patients with COPD without NTM-PD (15.9%; 62/390) [29]. The difference from our study was that it did not require patients to have COPD before their diagnosis of NTM-PD. In addition, a Japan-based analysis of 204 patients with NTM-PD in Nagasaki found that almost half (44.4%; 20 out of 45) of patients with NTM-PD who experienced clinical deterioration within 1 year had underlying lung disease, including COPD [10]. Collectively, these data underscore the need for timely and appropriate management of NTM-PD in high-risk patients with underlying lung disease.
The observed comparable burden of hospitalisation in the subgroup analysis between hospitalised cases and controls in the COPD group may reflect that patients who experienced hospitalisations might have had similar COPD severity; it is also possible that, once hospitalised, similar patterns of patient management were used in Japan, regardless of NTM-PD status.
During the 1-year period prior to the diagnosis of NTM-PD, the study found a consistently lower prevalence of asthma among the cases with NTM-PD compared with the controls without NTM-PD, in all the three patient groups; the difference was statistically significant in the COPD group and the COPD and bronchiectasis group. Similar results were reported from an analysis of patients with bronchiectasis enrolled in the US Bronchiectasis Research Registry, in which asthma was less common in patients with NTM-PD than without NTM-PD (25.7% versus 32.5%) [30]. In contrast, a US study that analysed claims data from patients aged ≥65 years reported a higher prevalence of asthma in patients with COPD with NTM-PD than in patients with COPD without NTM-PD (26.5% versus 17.3%) [31]. It has been reported that approximately 15–55% of patients may have asthma–COPD overlap syndrome, with variation seen by sex and age [32]. The prevalences of asthma in the different patient groups in our study were within the above range. The varying prevalence of comorbid asthma reported in the literature, as well as in our study, may be a combined effect of the differences in ages, race, and underlying respiratory diseases and their severities, as well as possible misdiagnosis of those conditions. Further investigations are needed to better understand the relationship between asthma, COPD, bronchiectasis and NTM-PD in Japan.
In agreement with previous studies, GORD was a common comorbidity observed in patients with COPD and/or bronchiectasis with or without NTM-PD in this analysis [13, 33–35]. The observation that GORD was more common in patients with COPD than with bronchiectasis, regardless of the presence of NTM-PD, may be related to the higher proportion of male patients and smokers in the COPD group, as both male sex and a history of smoking have been shown to be risk factors for GORD [13, 36].
Claims-based epidemiological research has inherent limitations, including lack of potentially pertinent clinical information in the claims database for confirming NTM-PD [12, 37, 38]. Variations in coding practices in Japan's healthcare systems might also affect patients’ clinical characteristics, such as the lower prevalence of cough and dyspnoea in this study than those in previous studies (ranging from 55% to 96%) [18, 39, 40]. Nevertheless, such differences in documenting the pulmonary symptoms in claims likely apply to both cases and controls and so should not affect our findings regarding the incremental burden associated with NTM-PD in Japan. Prevalence of COPD in Japan has been estimated to be approximately 10–15% in the general population and >30% among high-risk patients [41, 42], but underdiagnosis is well documented [41, 43, 44]. In this study, COPD was identified in <5% of the JMDC population, but any potential underdiagnosis likely affected both the case and control groups comparably. Some of the control group could be complicated with undiagnosed NTM-PD but this cannot be confirmed.
Hospitalisation for COPD exacerbation is positively correlated to COPD severity [45, 46]; it is possible patients with NTM-PD had more severe underlying COPD. However, COPD severity was not assessed due to key indicators [47] not being available in the claims data. Patient numbers in the bronchiectasis groups were small, precluding multivariable adjustment. Nonetheless, NTM-PD was associated with an incremental burden of hospitalisation in both bronchiectasis groups. Findings from the JMDC database are specific to individuals aged <75 years and might not apply to the older population in Japan, nor be generalisable to other countries [38].
This analysis provides the first large-scale population-based estimate of incremental hospitalisation burden associated with NTM-PD in patients with COPD and/or bronchiectasis in Japan. Since COPD and bronchiectasis are risk factors and common comorbidities of patients with NTM-PD, segmentation of patients with NTM-PD into mutually exclusive groups with either COPD, concomitant bronchiectasis and COPD, or bronchiectasis offers insights for better disease management. These findings add to prior studies that have highlighted burdens associated with NTM-PD, such as economic losses owing to the inability to work full-time and costs of long-term medication, as well as an increased risk of mortality [29, 31, 48]. The evidence from this study should help healthcare policy decision makers in Japan who need information on disease burden when making decisions on new medicines. Possible strategies that could enhance the current disease management include increasing the awareness of NTM-PD among physicians and patients in this subpopulation; encouraging early screening and diagnosis with sputum culture and chest imaging; initiating treatment rather than a watchful waiting approach; and maintaining patients on antibiotic treatment for ≥1 year after sputum culture conversion based on the guideline recommendations [23].
In conclusion, the substantial incremental hospitalisation burden associated with NTM-PD in patients with pre-existing COPD and/or bronchiectasis highlights the urgent need for appropriate management of NTM-PD in this subpopulation.
Supplementary material
Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.
Supplementary material 00911-2023.SUPPLEMENT (460.2KB, pdf)
Acknowledgements
The authors thank Kulvinder Katie Singh for medical writing support. Medical writing support was funded by Insmed Incorporated (Bridgewater, NJ, USA). Editorial support was provided by Tracey McManus of Envision Pharma Group and funded by Insmed Incorporated.
Provenance: Submitted article, peer reviewed.
Ethics statement: Ethics approval was not applicable to this study based on the Ethical Guidelines for Medical and Biological Research Involving Human Subjects issued by the Japanese Ministry of Health, Labour and Welfare, and Ministry of Economy, Trade and Industry, since the study did not involve any invasiveness or intervention, and only publicly available de-identified and encrypted data were used. Obtaining prior patient consent was not required or applicable under Article 76 (1) of the Act on the Protection of Personal Information.
Author contributions: P. Wang, K. Morimoto, N. Hasegawa, M. Hassan and A. Chatterjee substantially contributed to the conception and design of the study, data analysis, and interpretation of the data. All authors contributed to the drafting of the manuscript and read and approved the final manuscript.
Conflict of interest: P. Wang and M. Hassan are employees and shareholders of Insmed Incorporated.
Conflict of interest: K. Morimoto reports consulting fees from Insmed Incorporated.
Conflict of interest: N. Hasegawa served as a Scientific Research Study Investigator for Insmed Incorporated and Janssen Pharmaceuticals Inc. and reports consulting fees from Insmed Incorporated and Janssen Pharmaceuticals Inc.
Conflict of interest: A. Chatterjee was an employee of Insmed Incorporated at the time of this study.
Support statement: This study was supported by Insmed Incorporated (Bridgewater, NJ, USA). Funding information for this article has been deposited with the Crossref Funder Registry.
Data availability
statement: The data that support the findings of this study are included within the article (and its supplementary material).
References
- 1.Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175: 367–416. doi: 10.1164/rccm.200604-571ST [DOI] [PubMed] [Google Scholar]
- 2.Morimoto K, Iwai K, Uchimura K, et al. A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc 2014; 11: 1–8. doi: 10.1513/AnnalsATS.201303-067OC [DOI] [PubMed] [Google Scholar]
- 3.Wang P, Hassan M, Chatterjee A. The incremental burden of nontuberculous mycobacterial lung disease (NTMLD) among patients with chronic obstructive pulmonary disease (COPD): hospitalizations and ER visits among US Medicare beneficiaries. Open Forum Infect Dis 2020; 7: Suppl. 1, 748–749. doi: 10.1093/ofid/ofaa439.1674 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Prevots DR, Marras TK. Epidemiology of human pulmonary infection with nontuberculous mycobacteria: a review. Clin Chest Med 2015; 36: 13–34. doi: 10.1016/j.ccm.2014.10.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Winthrop KL, Marras TK, Adjemian J, et al. Incidence and prevalence of nontuberculous mycobacterial lung disease in a large U.S. managed care health plan, 2008-2015. Ann Am Thorac Soc 2020; 17: 178–185. doi: 10.1513/AnnalsATS.201804-236OC [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Ringshausen FC, Wagner D, de Roux A, et al. Prevalence of nontuberculous mycobacterial pulmonary disease, Germany, 2009–2014. Emerg Infect Dis 2016; 22: 1102–1105. doi: 10.3201/eid2206.151642 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Park SC, Kang MJ, Han CH, et al. Prevalence, incidence, and mortality of nontuberculous mycobacterial infection in Korea: a nationwide population-based study. BMC Pulm Med 2019; 19: 140. doi: 10.1186/s12890-019-0901-z [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Izumi K, Morimoto K, Hasegawa N, et al. Epidemiology of adults and children treated for nontuberculous mycobacterial pulmonary disease in Japan. Ann Am Thorac Soc 2019; 16: 341–347. [DOI] [PubMed] [Google Scholar]
- 9.Namkoong H, Kurashima A, Morimoto K, et al. Epidemiology of pulmonary nontuberculous mycobacterial disease, Japan. Emerg Infect Dis 2016; 22: 1116–1117. doi: 10.3201/eid2206.151086 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Ide S, Nakamura S, Yamamoto Y, et al. Epidemiology and clinical features of pulmonary nontuberculous mycobacteriosis in Nagasaki, Japan. PLoS One 2015; 10: e0128304. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Ito Y, Hirai T, Maekawa K, et al. Predictors of 5-year mortality in pulmonary Mycobacterium avium-intracellulare complex disease. Int J Tuberc Lung Dis 2012; 16: 408–414. doi: 10.5588/ijtld.11.0148 [DOI] [PubMed] [Google Scholar]
- 12.Marras TK, Vinnard C, Zhang Q, et al. Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population. Respir Med 2018; 145: 80–88. doi: 10.1016/j.rmed.2018.10.022 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Uno S, Asakura T, Morimoto K, et al. Comorbidities associated with nontuberculous mycobacterial disease in Japanese adults: a claims-data analysis. BMC Pulm Med 2020; 20: 262. doi: 10.1186/s12890-020-01304-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Chandrasekaran R, Mac Aogáin M, Chalmers JD, et al. Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC Pulm Med 2018; 18: 83. doi: 10.1186/s12890-018-0638-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Takada Y, Sakai F, Suzuki K, et al. CT features of pulmonary nontuberculous mycobacterial infection: effects of underlying pulmonary disease. Radiat Med 2000; 18: 167–175. [PubMed] [Google Scholar]
- 16.Ryu YJ, Koh WJ, Daley CL. Diagnosis and treatment of nontuberculous mycobacterial lung disease: clinicians’ perspectives. Tuberc Respir Dis (Seoul) 2016; 79: 74–84. doi: 10.4046/trd.2016.79.2.74 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Daley CL, Winthrop KL. Mycobacterium avium complex: addressing gaps in diagnosis and management. J Infect Dis 2020; 222: Suppl. 4, 199–211. doi: 10.1093/infdis/jiaa354 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Kim RD, Greenberg DE, Ehrmantraut ME, et al. Pulmonary nontuberculous mycobacterial disease: prospective study of a distinct preexisting syndrome. Am J Respir Crit Care Med 2008; 178: 1066–1074. doi: 10.1164/rccm.200805-686OC [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Maiga M, Siddiqui S, Diallo S, et al. Failure to recognize nontuberculous mycobacteria leads to misdiagnosis of chronic pulmonary tuberculosis. PLoS One 2012; 7: e36902. doi: 10.1371/journal.pone.0036902 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Wang P, Marras TK, Alemao E, et al. Identifying potentially undiagnosed nontuberculous mycobacterial lung disease among patients with chronic obstructive pulmonary disease: development of a predictive algorithm using claims data. Am J Respir Crit Care Med 2021; 203: A3940. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Larsson LO, Polverino E, Hoefsloot W, et al. Pulmonary disease by non-tuberculous mycobacteria – clinical management, unmet needs and future perspectives. Expert Rev Respir Med 2017; 11: 977–989. [DOI] [PubMed] [Google Scholar]
- 22.Wang P, Marras TK, Alemao E, et al. How does mortality differ in early vs. late diagnosed nontuberculous mycobacterial lung disease among patients with chronic obstructive pulmonary disease (COPD). Value in Health 2021; 24: Suppl. 1, S111. doi: 10.1016/j.jval.2021.04.1221 [DOI] [Google Scholar]
- 23.Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Eur Respir J 2020; 56: 2000535. doi: 10.1183/13993003.00535-2020 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Wang P, Marras T, Alemao E, et al. The incremental burden of nontuberculous mycobacterial lung disease (NTMLD) among patients with bronchiectasis (BE): hospitalizations and ER visits among US Medicare beneficiaries. Eur Respir Pulmon Dis 2020; 6: Suppl. 2, 33–35. [Google Scholar]
- 25.Nagai K, Tanaka T, Kodaira N, et al. Data resource profile: JMDC claims database sourced from health insurance societies. J Gen Fam Med 2021; 22: 118–127. doi: 10.1002/jgf2.422 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Ministry of Education Culture, Sports, Science and Technology , Ministry of Health, Labour and Welfare , Ministry of Economy, Trade and Industry . [Ethical guidelines for medical and biological research involving human subjects]. https://www.mhlw.go.jp/content/000757566.pdf. Date last updated: 2022. Date last accessed: 4 January 2022.
- 27.Ku JH, Henkle EM, Carlson KF, et al. Validity of diagnosis code-based claims to identify pulmonary NTM disease in bronchiectasis patients. Emerg Infect Dis 2021; 27: 982–985. doi: 10.3201/eid2703.203124 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Seifer FD, Hansen G, Weycker D. Health-care utilization and expenditures among patients with comorbid bronchiectasis and chronic obstructive pulmonary disease in US clinical practice. Chron Respir Dis 2019; 16: 1479973119839961. doi: 10.1177/1479973119839961 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Diel R, Jacob J, Lampenius N, et al. Burden of non-tuberculous mycobacterial pulmonary disease in Germany. Eur Respir J 2017; 49: 1602109. doi: 10.1183/13993003.02109-2016 [DOI] [PubMed] [Google Scholar]
- 30.Aksamit TR, O'Donnell AE, Barker A, et al. Adult patients with bronchiectasis: a first look at the US bronchiectasis research registry. Chest 2017; 151: 982–992. doi: 10.1016/j.chest.2016.10.055 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Wang P, Marras TK, Hassan M, et al. Incremental mortality associated with nontuberculous mycobacterial lung disease among US Medicare beneficiaries with chronic obstructive pulmonary disease. BMC Infect Dis 2023; 23: 749. doi: 10.1186/s12879-023-08689-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Inoue H, Nagase T, Morita S, et al. Prevalence and characteristics of asthma–COPD overlap syndrome identified by a stepwise approach. Int J Chron Obstruct Pulmon Dis 2017; 12: 1803–1810. doi: 10.2147/COPD.S133859 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Kim Y, Yoon JH, Ryu J, et al. Gastroesophageal reflux disease increases susceptibility to nontuberculous mycobacterial pulmonary disease. Chest 2023; 163: 270–280. doi: 10.1016/j.chest.2022.08.2228 [DOI] [PubMed] [Google Scholar]
- 34.Koh WJ, Lee JH, Kwon YS, et al. Prevalence of gastroesophageal reflux disease in patients with nontuberculous mycobacterial lung disease. Chest 2007; 131: 1825–1830. doi: 10.1378/chest.06-2280 [DOI] [PubMed] [Google Scholar]
- 35.Thomson RM, Armstrong JG, Looke DF. Gastroesophageal reflux disease, acid suppression, and Mycobacterium avium complex pulmonary disease. Chest 2007; 131: 1166–1172. doi: 10.1378/chest.06-1906 [DOI] [PubMed] [Google Scholar]
- 36.Watanabe Y, Fujiwara Y, Shiba M, et al. Cigarette smoking and alcohol consumption associated with gastro-oesophageal reflux disease in Japanese men. Scand J Gastroenterol 2003; 38: 807–811. doi: 10.1080/00365520310004506 [DOI] [PubMed] [Google Scholar]
- 37.Mejia-Chew C, Yaeger L, Montes K, et al. Diagnostic accuracy of health care administrative diagnosis codes to identify nontuberculous mycobacteria disease: a systematic review. Open Forum Infect Dis 2021; 8: ofab035. doi: 10.1093/ofid/ofab035 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Suzuki S, Desai U, Strizek A, et al. Characteristics, treatment patterns, and economic outcomes of patients initiating injectable medications for management of type 2 diabetes mellitus in Japan: results from a retrospective claims Database Analysis. Diabetes Ther 2018; 9: 1125–1141. doi: 10.1007/s13300-018-0407-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-sectional study. Eur Respir J 2011; 37: 264–272. doi: 10.1183/09031936.00051110 [DOI] [PubMed] [Google Scholar]
- 40.King PT, Holdsworth SR, Freezer NJ, et al. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med 2006; 100: 2183–2189. doi: 10.1016/j.rmed.2006.03.012 [DOI] [PubMed] [Google Scholar]
- 41.Tanabe N, Sato S. Narrative review of current COPD status in Japan. J Thorac Dis 2021; 13: 3878–3887. doi: 10.21037/jtd-20-2263 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Ogata H, Hirakawa Y, Matsumoto K, et al. Trends in the prevalence of airflow limitation in a general Japanese population: two serial cross-sectional surveys from the Hisayama Study. BMJ Open 2019; 9: e023673. doi: 10.1136/bmjopen-2018-023673 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Onishi K, Yoshimoto D, Hagan GW, et al. Prevalence of airflow limitation in outpatients with cardiovascular diseases in Japan. Int J Chron Obstruct Pulmon Dis 2014; 9: 563–568. doi: 10.2147/COPD.S59962 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Fukahori S, Matsuse H, Takamura N, et al. Prevalence of chronic obstructive pulmonary diseases in general clinics in terms of FEV1/FVC. Int J Clin Pract 2009; 63: 269–274. doi: 10.1111/j.1742-1241.2008.01873.x [DOI] [PubMed] [Google Scholar]
- 45.Kong CW, Wilkinson TMA. Predicting and preventing hospital readmission for exacerbations of COPD. ERJ Open Res 2020; 6: 00325-2019. doi: 10.1183/23120541.00325-2019 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Tsoumakidou M, Tzanakis N, Voulgaraki O, et al. Is there any correlation between the ATS, BTS, ERS and GOLD COPD's severity scales and the frequency of hospital admissions? Respir Med 2004; 98: 178–183. doi: 10.1016/j.rmed.2003.09.011 [DOI] [PubMed] [Google Scholar]
- 47.Global Initiative for Chronic Obstructive Lung Disease . Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2021 report. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Date last accessed 25 October 2021
- 48.Laan R, Hoening C, Legtenberg R, et al. Patient-reported burden of nontuberculous mycobacterial lung disease – results from a European patient survey. Eur Respir J 2023; 62: Suppl. 67, PA2166. doi: 10.1183/13993003.congress-2023.PA2166 [DOI] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Please note: supplementary material is not edited by the Editorial Office, and is uploaded as it has been supplied by the author.
Supplementary material 00911-2023.SUPPLEMENT (460.2KB, pdf)
Data Availability Statement
statement: The data that support the findings of this study are included within the article (and its supplementary material).